If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-09. Numbers and descriptions here follow the published literature rather than marketing material.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
So, in addition to the general discovery of target specific molecular compounds, the availability of binders to pharmacologically important, but so-far “undruggable” target proteins opens new possibilities to develop novel drugs for diseases that could not be treated so far. In eliminating the requirement to initially assess the activity of hits it is hoped and expected that many of the high affinity binders identified will be shown to be active in independent analysis of selected hits, therefore offering an efficient method to identify high quality hits and pharmaceutical leads.
=== Conservative === There is currently no medical recommendation about how to manage an inguinal hernia condition in adults, due to the fact that, until the early 2010s, elective surgery used to be recommended. The hernia truss (or hernia belt) is intended to contain a reducible inguinal hernia within the abdomen. It is not considered to provide a cure, and if the pads are hard and intrude into the hernia aperture, they may cause scarring and enlargement of the aperture. In addition, most trusses with older designs are unable to effectively contain the hernia at all times, because their pads do not remain permanently in contact with the hernia. The more modern variety of truss is made with non-intrusive flat pads and comes with a guarantee to hold the hernia securely during all activities. They have been described by users as providing greater confidence and comfort when carrying out physically demanding tasks. However, their use is controversial, as data to determine whether they help prevent hernia complications is lacking. A truss also increases the probability of complications, which include strangulation of the hernia, atrophy of the spermatic cord, and atrophy of the fascial margins. This allows the defect to enlarge and makes subsequent repair more difficult. Their popularity is nonetheless likely to increase, as many individuals with small, painless hernias are now delaying hernia surgery due to the risk of post-herniorrhaphy pain syndrome. Elasticated pants used by athletes may also provide useful support for the smaller hernia.
=== Neurotoxicity === Laboratory studies in rats indicate that ibogaine at high doses may cause degeneration of Purkinje cells in the cerebellum. This also occurred with the related drug harmaline. However, subsequent research found no evidence of this neurotoxicity with ibogaine in a primate. In limited human research, neuropathological examination revealed no evidence of neuronal degenerative changes in an adult female patient who had received four separate doses of ibogaine ranging between 10 and 30 mg/kg over a 15-month interval. A published series of fatalities associated with ibogaine ingestion also found no evidence for consistent neurotoxicity.
== Production == Yeast extracts in general are produced in three steps: fermentation (growing the yeast), disruption (breaking of the cells), and separation (to keep the soluble part). Although the vast majority of yeast extract spreads are made using von Liebig's traditional approach of heat-autolysis using surplus yeast from beer brewing, other methods do exist for producing specialized types. In terms of fermentation, spent beer yeast is commonly contaminated with the bitter compounds from hops, requiring a "debittering" step to wash out most of this undesired flavor. Yeast from other sources are not affected by this issue. Spent brewer's yeast is also quite biodiverse, containing yeasts other than traditional Saccharomyces cerevisiae and sometimes beer spoilage-causing lactic acid bacteria too. For disruption of the cell, some physical and chemical methods may be used in place of the heat-autolysis process. Doing so may allow specific compounds to be extracted or to produce an extract without the hydrolysis of cell contents (as in autolysis) happening. Autolysis can be assisted with added enzymes; for example, additional nuclease would enhance the release of nucleosides from RNA. Separation removes insoluble parts, mainly the yeast's cell wall, from the extract. Cell wall can be separated into two commercially useful parts: the glucans as "yeast β-glucan" and the mannans further processed into mannan-oligosaccharide (MOS). The product is finally concentrated by drying, into a thick paste or a dry powder.
Junalis was also responsible for killing another taxi driver Seing Koo Wan. 1995: Jamaludin Ibrahim, a Singaporean repairman who killed his two neighbours after robbing them. He was hanged on 28 July 1995. 1996: Panya Marmontree, Prawit Yaowabutr, Manit Wangjaisuk, Panya Amphawa, and Prasong Bunsom, all citizens of Thailand, hanged on 15 March 1996 for the murders of three men during an island-wide spree of construction site robberies between November 1992 and September 1993. 1996: John Martin Scripps, a British serial killer hanged on 19 April 1996 for murdering three tourists. 1996: Zainal Abidin Abdul Malik, a 29-year-old Singaporean who used an axe to murder 47-year-old police officer Boo Tiang Huat. He was convicted for murder and hanged on 30 August 1996. 1998: Jimmy Chua Hwa Soon, a former army sergeant who killed his sister-in-law and slashed his nephew. He was sentenced to death for murder in April 1997 and lost his appeal in February 1999: Jonaris Badlishah, a Malaysian and nephew of the Sultan of Kedah who was sentenced to death for the 1998 murder of Sally Poh Bee Eng and theft of her Rolex watch. He lost his appeal in February 1999, and afterwards, he was hanged. 1999: S. Nagarajan Kuppusamy, a Singaporean lorry driver found guilty of murdering a prison warden and put to death on 23 July 1999. 2002: Three men - Rosli bin Ahmat, Wan Kamil bin Mohamed Shafian, and Ibrahim bin Mohamed - were executed on 25 October 2002 for the August 2000 murders of Koh Ngiap Yong and Jahabar Sathick at Chestnut Avenue and Jalan Kukoh respectively.
Sources: en.wikipedia.org
Anti-parasitic: Calotropis extracts have been used in traditional medicine to treat parasitic infections. Some compounds in the plant have demonstrated activity against certain parasites. Calotropis contains toxic compounds, particularly in its latex and other plant parts. Using Calotropis for its potential medicinal properties, it's best to consult a qualified healthcare professional who can provide guidance based on your specific health needs and conditions.
==== Multi-printhead and multi-material ==== In multi-printhead and multi-material printing, multiple ingredients are printed at the same time or in succession. There are different ways to support multi-material printing. In one instance, multiple printheads are used to print multiple materials/ingredients, as this can speed up production, efficiency, and lead to interesting design patterns. In another instance, there is one printhead, and when a different ingredient is required, the printer exchanges the material being printed. Multiple materials/ingredients equates to a more diverse range of meals available to print, a broader nutritional range, and is quite common for food printers.
Sanjay Kalra (born 18 April 1970) is an Indian endocrinologist working at Bharti Hospital in Karnal, Haryana. Kalra is a former president of the Endocrine Society of India, the South Asian Federation of Endocrine Societies, and the Indian Professional Association for Transgender Health. He has also served on the executive council of the Research Society for the Study of Diabetes in India. Kalra has more than 1,000 PubMed-indexed articles to his credit, and has contributed to strengthening bilateral and multilateral collaborations between various African and Asian countries in the field of endocrinology. He has developed several terms and concepts, including glucokathexis, lipokathexis, glucocrinology, ipocrinology, glycaemic hygiene, endocrine hygiene, and ergonomic endocrinology. He also invented the GlucoCoper tool to assess psychological coping mechanisms in people with diabetes. In addition, he has published work on the concepts of diabetes fatigue syndrome, euthymia in diabetes, quaternary prevention in endocrinology, and quinary prevention.
Though a good signal may be achieved through glycerol or glycerol with an additive, there could be other matrix compounds that can offer an even better signal. Optimization of matrix compounds and concentration of solid analyte are vital for FAB measurements.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.